Slayback Pharma Limited Liability Company
Slayback Pharma Limited Liability Company, commonly referred to as Slayback Pharma, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 2017, the company has rapidly established itself in the development and commercialisation of complex generic and specialty pharmaceuticals, focusing on areas such as oncology and neurology. With a commitment to innovation, Slayback Pharma offers a unique portfolio of products that address unmet medical needs, setting them apart in a competitive market. The company has achieved significant milestones, including successful product launches and strategic partnerships, which have bolstered its market position. As Slayback Pharma continues to expand its operational reach, it remains dedicated to improving patient outcomes through high-quality, accessible medications.
DitchCarbon Score
How does Slayback Pharma Limited Liability Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Slayback Pharma Limited Liability Company's score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Slayback Pharma Limited Liability Company's reported carbon emissions
Slayback Pharma Limited Liability Company, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year. As such, there are no specific figures regarding their Scope 1, 2, or 3 emissions. Additionally, the company has not outlined any formal reduction targets or commitments to the Science Based Targets initiative (SBTi) or similar climate pledges. In the absence of concrete emissions data, it is important to note that many companies in the pharmaceutical industry are increasingly focusing on sustainability and reducing their carbon footprints. Slayback Pharma may be engaging in similar initiatives, although specific details are not provided. The company’s commitment to addressing climate change and reducing environmental impact remains unclear without further information.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Slayback Pharma Limited Liability Company is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
